antibody

JAM-A, Human, mAb M.Ab.F11

MBS584196

0.1 mg

665 USD

monoclonal

mouse

nonconjugated

Antibody

JAM-A, Human, mAb M.Ab.F11

[JAM-A]

[Junction Adhesion Molecule, JAM-1, platelet F11 receptor, F11R, platelet adhesion molecule, CD321]

[Junctional adhesion molecule A; Junctional adhesion molecule A; junctional adhesion molecule A; platelet F11 receptor; platelet adhesion molecule 1; junctional adhesion molecule 1; F11 receptor; Junctional adhesion molecule 1; JAM-1; Platelet F11 receptor; Platelet adhesion molecule 1; PAM-1; CD_antigen: CD321]

[JAM-A]

[F11R; F11R; JAM; KAT; JAM1; JAMA; JCAM; CD321; PAM-1; JAM1; JCAM; UNQ264/PRO301; JAM-A; JAM-1; PAM-1]

JAM1_HUMAN

Monoclonal

IgG1

Mouse

299

Protein G

0.2 um filtered in PBS+0.1% BSA

Product should be stored at 4 degree C. Under recommended storage conditions, product is stable for at least one year.

Yes: Immunohistochemistry - Paraffin (IHC-P), Immunofluorescence (IF), Flow Cytometry (FC), Functional Studies (FS), Immunoassay (IA), Immunoprecipitation (IP), Western Blot (WB); Not Determined: Immunohistochemistry - Frozen (IHC-F).

Dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. - FC: Antibody M.Ab. F11 stains the extracellular domain of JAM-A protein name. Cells were incubated with 5ug/ml of mAb in 0.1% BSA/PBS. As negative control an isotype-matched antibody was used (Ref. 4). - WB: A non-reduced and reduced sample treatment and SDS-PAGE was used. The band sizes are 32 and 35 kDa (Ref. 1). - FS: Antibody M.Ab. F11 functions as anagonist resulting in platelet aggregation at concentrations of approximately 5 ug/ml (Ref. 1).

Endotoxin: < 0.4 EU/mg. Conjuagte: None. Immunogen: Human platelet membranes.

The monoclonal antibody M.Ab.F11 recognizes junctional adhesion molecule-A (JAM-A) also known as the human platelet F11-Receptor (F11R) or JAM-1. JAM-A is a surface glycoprotein duplex (32 and 35 kDa) belongingto the immunoglobulin superfamily found on the surface of human platelets and at intercellular junctions of endothelial cells and epithelial cells. JAM-A belongs together with JAM-C (JAM-2) and JAM-B (VE-JAM or JAM-3) to a family of adhesion proteins with a V-C2 immunoglobulin domain organization. JAM-A plays an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interactions. It co-distributes with other tight junction components such as ZO-1, 7H6 antigen, cingulin and occludin. Moreover, JAM-A plays a role in platelet aggregation, secretion, adhesion, spreading. In the platelet, JAM-A is a membrane protein involved in 2 distinct processes initiated on the platelet surface. Namely,, antibody-induced platelet aggregation and secretion both dependent on FcgammaRII and GPIIb/IIIa integrin, a process that may be involved in pathophysiological processes associated with certain thrombocytopenias and secondly, antibody mediated platelet adhesion independent from FcgammaRII or- fibrinogen receptor that appears to play a role in physiological processes associated with platelet adhesion and aggregation. A physiological role for the JAM-A protein was demonstrated by its phosphorylation after the stimulation of platelets by thrombin and collagen. A pathophysiological role for the JAM-A was revealed by demonstrating the presence of JAM-A antibodies in patients with thrombocytopenia. Adhesion of platelets through JAM-A resulted in events characteristic of the action of cell adhesion molecules. Recent data suggests a role for JAM-A in the adhesion of platelets to cytokine-inflamed endothelial cells and thus in thrombosis and atherosclerosis induced in non-denuded blood vessels by inflammatory processes.

1. Kornecki, E et al; Activation of human platelets by a stimulatory monoclonal antibody. J Biol Chem 1990, 265: 10042 2. Naik, U et al; Mechanisms of platelet activation by a stimulatory antibody: cross-linking of a novel platelet receptor for monoclonal antibody F11 with the Fc gamma RII receptor. Biochem J 1995, 310: 155. 3. Wang, F et al; Stimulatory antibody-induced activation and selective translocation of protein kinase C isoenzymes in human platelets. Biochem J 1995, 311: 401. 4. Sobocka, M et al; Cloning of the human platelet F11 receptor: a cell adhesion molecule member of the immunoglobulin superfamily involved in platelet aggregation. Blood 2000, 95: 2600. 5. Babinska, A et al; Two regions of the human platelet F11-receptor (F11R) are critical for platelet aggregation, potentiation and adhesion. Thromb Haemost 2002, 87: 712. 6. Babinska, A et al; The F11 receptor (F11R/JAM-A) in atherothrombosis: overexpression of F11R in atherosclerotic plaques. Thromb Haemost 2007, 97: 272. 7. Cavusoglu, E et al; Association of plasma levels of F11 receptor/junctional adhesion molecule-A (F11R/JAM-A) with human atherosclerosis. JACC 2007, 50: 1768. 8. Koenen, R et al; Regulated release and functional modulation of junctional adhesion molecule A by disintegrin metalloproteinases. Blood 2009, 113: 4799

10720061

Q9Y624.1

Cell Adhesion Molecules (CAMs) Pathway (83069); Cell Adhesion Molecules (CAMs) Pathway (480); Cell Junction Organization Pathway (160966); Cell Surface Interactions At The Vascular Wall Pathway (106062); Cell-Cell Communication Pathway (477132); Cell-cell Junction Organization Pathway (119532); Disease Pathway (530764); Epithelial Cell Signaling In Helicobacter Pylori Infection Pathway (83102); Epithelial Cell Signaling In Helicobacter Pylori Infection Pathway (515); Extracellular Matrix Organization Pathway (576262)

Tight junctions represent one mode of cell-to-cell adhesion in epithelial or endothelial cell sheets, forming continuous seals around cells and serving as a physical barrier to prevent solutes and water from passing freely through the paracellular space. The protein encoded by this immunoglobulin superfamily gene member is an important regulator of tight junction assembly in epithelia. In addition, the encoded protein can act as (1) a receptor for reovirus, (2) a ligand for the integrin LFA1, involved in leukocyte transmigration, and (3) a platelet receptor. Multiple 5' alternatively spliced variants, encoding the same protein, have been identified but their biological validity has not been established. [provided by RefSeq, Jul 2008]

JAM-A: Seems to play a role in epithelial tight junction formation. Appears early in primordial forms of cell junctions and recruits PARD3. The association of the PARD6-PARD3 complex may prevent the interaction of PARD3 with JAM1, thereby preventing tight junction assembly. Plays a role in regulating monocyte transmigration involved in integrity of epithelial barrier. Involved in platelet activation. In case of orthoreovirus infection, serves as receptor for the virus. Belongs to the immunoglobulin superfamily. Protein type: Cell adhesion; Membrane protein, integral. Chromosomal Location of Human Ortholog: 1q21.2-q21.3. Cellular Component: microtubule cytoskeleton; tight junction; plasma membrane; integral to membrane; cytoplasmic vesicle; intercellular junction; cell junction. Molecular Function: protein binding; PDZ domain binding. Biological Process: intercellular junction assembly and maintenance; extracellular matrix organization and biogenesis; response to radiation; viral reproduction; transforming growth factor beta receptor signaling pathway; actomyosin structure organization and biogenesis; blood coagulation; cell adhesion; inflammatory response; leukocyte migration; positive regulation of blood pressure; intestinal absorption

0.1 mg

665 USD